The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
 
Margaret A. Tempero
Honoraria - Oregon Health & Science University (OHSU)
Consulting or Advisory Role - Abbvie; Advance Medical; Astellas Pharma; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene (Inst); CPRIT; EcoR1 Capital; Eisai; FibroGen (Inst); Halozyme (Inst); Ignyta; Immunovia; Merck; Pharmacyclics; Pharmacyte Biotech; Tocagen
Research Funding - Celgene (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene; CPRIT; Eisai; Halozyme; Pharmacyclics; Pharmacyte Biotech; Tocagen
 
Michele Reni
Honoraria - Baxalta/Shire
Consulting or Advisory Role - Baxalta/Shire; Celgene; Novartis; Novocure; Pfizer
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene
 
Hanno Riess
Consulting or Advisory Role - Celgene; Roche; Shire
 
Uwe Pelzer
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Jordan Michael Winter
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; EMD Serono; Genentech; Merck; Novartis; Roche; Taiho Pharmaceutical
Research Funding - Array BioPharma; AstraZeneca; Green Cross; Lilly; Novartis
 
Chung-Pin Li
No Relationships to Disclose
 
Giampaolo Tortora
Consulting or Advisory Role - Celgene; Merck Serono
Travel, Accommodations, Expenses - Merck Serono; Roche
 
Heung-Moon Chang
Research Funding - ASLAN Pharmaceuticals; Celgene; Halozyme; Pharmacyclics; Senhwa Biosciences; Taiho Pharmaceutical
 
Charles D. Lopez
Consulting or Advisory Role - Boston Biomedical; Boston Scientific; Celgene; Exelixis; Pfizer
Travel, Accommodations, Expenses - RenovoRx
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Eric Van Cutsem
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Philip Agop Philip
Honoraria - Amgen; ASLAN Pharmaceuticals; Bayer; Biologics; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Lexi Pharma; Merck; Novartis; Rafael Pharmaceuticals; Sanofi
Consulting or Advisory Role - Celgene; Halozyme; Ipsen; Merck; Merrimack; novartis; Rafael Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); tyme (Inst); TYME (Inst)
Other Relationship - Halozyme
 
David Goldstein
Stock and Other Ownership Interests - Sirtex Medical
Consulting or Advisory Role - sun biopharma
Research Funding - Amgen (Inst); Bayer (Inst); Celgene (Inst); pfizer (Inst)
 
Jordan Berlin
Honoraria - Nestle health science
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Bayer Health; BeiGene; Celgene; Cornerstone Pharmaceuticals; Eisai; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; lsk biopharma; Seagen
Research Funding - Bayer (Inst); BeiGene (Inst); boston biomedical (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Pharmacyclics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; Bayer; EMD Serono; Nestle health science; Seagen
Other Relationship - AstraZeneca
 
Stefano Ferrara
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Mingyu Li
Employment - Celgene
Other Relationship - Celgene
 
Brian D. Lu
Employment - Celgene
Stock and Other Ownership Interests - Celgene
 
Andrew Biankin
Consulting or Advisory Role - AstraZeneca; Celgene; Clovis Oncology